Kardigan, Inc. (KARD)
| Market Cap | 2.11B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -229.99M |
| Shares Out | 89.34M |
| EPS (ttm) | -16.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 851,572 |
| Open | 22.27 |
| Previous Close | 22.58 |
| Day's Range | 21.88 - 24.54 |
| 52-Week Range | 16.25 - 24.86 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About KARD
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The... [Read more]
Financial Performance
Financial StatementsNews
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.
Opening Day: Kardigan races higher after debut on Nasdaq
Kardigan shares jumped on Thursday after the heart-health focused biotech raised $400M in an initial public offering. The stock opened at $16.25 and closed its first day of trade near…
Kardigan rises in Nasdaq debut after upsized $400 million IPO
Kardigan's shares rose 1.6% in their Nasdaq debut on Thursday, after the heart drug developer raised $400 million in an upsized U.S. initial public offering.
Kardigan opens at $16.25, IPO priced at $16.00
Kardiga, a clinical-stage precision therapeutics company developing medicines that target cardiovascular diseases, priced its initial public offering of 25M shares of common stock at $16 per share. Th...
Kardigan 25M share IPO priced at $16.00
The deal size was increased to 25.0M from 23.3M shares and priced at high end of $14.00-$16.00 range. JPMorgan, Jefferies, Leerink and TD Cowen are acting as joint book running…
Kardigan Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines th...
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
Kardigan is targeting a valuation of up to $1.4 billion in its initial public offering in the United States, the drug developer said on Thursday.
Cardiovascular drug developer Kardigan files for US IPO
Cardiovascular drug developer Kardigan on Tuesday filed for an initial public offering in the United States.
Kardigan IPO Registration Document (S-1)
Kardigan has filed to go public with an IPO on the NASDAQ